Antibody constructs for CDH19 and CD3

US12297292B2 · kind B2 · utility

Assignees

• AMGEN INC. · US
• AMGEN RESEARCH (MUNICH) GMBH · DE

Inventors

• Shouhua Xiao · Foster City, US
• Zheng Pan · Beijing, CN
• Dineli Wickramasinghe · San Francisco, US
• Peter Kufer · Munich, DE
• Patrick Hoffmann · Munich, DE
• Tobias Raum · Munich, DE
• Ralf Lutterbüse · Munich, DE
• Elisabeth Nahrwold · Munich, DE
• Claudia Blümel · Munich, DE

Key dates

• Filing date: Aug 10, 2017
• Grant date: May 13, 2025
• Expiry date: Aug 10, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A bispecific antibody construct comprising a first human binding domain which binds to human CDH19 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. A nucleic acid comprising a polynucleotide encoding the antibody construct, a vector comprising the nucleic acid comprising the polynucleotide and a host cell transformed or transfected with the nucleic acid comprising the polynucleotide or vector. A process for the production of the antibody construct, a medical use of the antibody construct in the treatment of melanoma, and a kit comprising the antibody construct.